10-KPeriod: FY2024

Edwards Lifesciences Corp Annual Report, Year Ended Dec 31, 2024

Filed February 28, 2025For Securities:EW

Summary

Edwards Lifesciences Corporation reported strong performance in its 2024 fiscal year, with net sales reaching $5.4 billion, an increase of 8.6% year-over-year. This growth was primarily driven by robust sales in its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. The company also made significant strategic moves, including the sale of its Critical Care product group for $4.2 billion and several key acquisitions aimed at strengthening its position in structural heart disease and expanding into heart failure management. Key financial highlights include a notable increase in net income and diluted earnings per share, supported by top-line growth and the positive impact of the Critical Care divestiture. The company's commitment to innovation is evident in its continued investment in research and development, representing 19% of net sales in 2024, with advancements in its TAVR and TMTT platforms. Edwards Lifesciences remains focused on its patient-centric strategy, aiming to transform care for those with structural heart disease and expanding its reach in interventional heart failure technologies.

Financial Highlights

52 data points
Beta

Revenue

$5.44B

79.5% Gross Margin

Net Income

$4.17B

76.7% Net Margin

EPS (Diluted)

$6.97

Total Assets

$13.06B

Cash & Equivalents

$3.06B

Free Cash Flow

$289.90M

Financial Statements
Beta
Revenue$5.44B
Cost of Revenue$1.12B
Gross Profit$4.32B
R&D Expenses$1.05B
SG&A Expenses$1.79B
Operating Income$1.38B
Net Income$4.17B
EPS (Basic)$6.98
EPS (Diluted)$6.97
Shares Outstanding (Basic)597.70M
Shares Outstanding (Diluted)599.30M

Key Highlights

  • 1Net sales increased by 8.6% to $5.4 billion, driven by TAVR and TMTT product growth.
  • 2Successfully completed the sale of its Critical Care product group for $4.2 billion, refocusing the company on structural heart and heart failure.
  • 3Acquired Endotronix, Inc., Innovalve Bio Medical Ltd., and JC Medical, Inc. to bolster its portfolio in heart failure management and transcatheter mitral replacement/regurgitation.
  • 4Research and Development (R&D) investment increased by 9% year-over-year, representing 19% of net sales, underscoring commitment to innovation.
  • 5Received FDA approval and launched the EVOQUE tricuspid valve replacement system in the U.S.
  • 6Announced positive results from key clinical trials such as EARLY TAVR and TRISCEND II, supporting the adoption of early intervention and new therapies.
  • 7Repurchased $1.2 billion of common stock in 2024, demonstrating a commitment to shareholder returns.

Frequently Asked Questions

Edwards Lifesciences' net sales increased by 8.6% to $5.4 billion in 2024. The primary drivers of this growth were higher sales of Transcatheter Aortic Valve Replacement (TAVR) products, particularly the Edwards SAPIEN 3 Ultra RESILIA valve, and strong performance in Transcatheter Mitral and Tricuspid Therapies (TMTT), fueled by the PASCAL repair system and the launch of the EVOQUE tricuspid valve replacement system.

The divestiture of the Critical Care product group for $4.2 billion allows Edwards Lifesciences to concentrate resources and investments on its core structural heart disease business, specifically TAVR and TMTT, and to accelerate its expansion into interventional heart failure technologies. The acquisitions of Endotronix, Innovalve Bio Medical, and JC Medical directly support this strategy by strengthening its offerings in heart failure management and advancing its transcatheter mitral valve technologies.

Edwards Lifesciences faces ongoing legal proceedings, including patent infringement claims and securities class actions, as detailed in the filing. The company is actively defending itself against these claims. Furthermore, the company operates in a highly regulated industry and is subject to stringent requirements from agencies like the FDA and EU MDR, which necessitate significant compliance efforts and carry potential risks of delays or penalties. The company proactively manages these risks through robust compliance programs and by investing in regulatory expertise.

Edwards Lifesciences demonstrated a strong commitment to R&D by investing 19% of its net sales in 2024, a 9% increase year-over-year. This investment is focused on developing innovative therapies for structural heart disease, including advancements in TAVR and TMTT, as well as exploring new interventional heart failure technologies. Key R&D achievements in 2024 include enrollment completion in pivotal trials and the launch of new products, which are expected to drive future growth and reinforce market leadership.